Noncoding RNA MEG3 inhibitor for Heart Failure Treatment

Project description

An RNA-based treatment for heart failure

Heart failure is associated with cardiac fibrosis or scarring, an unavoidable consequence of myocardial insult that affects diastolic and systolic function. Despite its great socioeconomic burden, there are no treatments to restore cardiac fibrosis and cure heart failure. The EU-funded MEGFIB project proposes to develop a new approach for treating selected heart failure patients, based on non-coding RNAs, which are emerging as important players in disease pathogenesis. Using oligonucleotides that target the meg3 long non-coding RNA in human cells and tissues, scientists hope to replicate their results in animal models and establish a new approach in heart failure care.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• medical and health sciences › basic medicine › pathology
• natural sciences › biological sciences › genetics › RNA
• medical and health sciences › clinical medicine › cardiology
• natural sciences › biological sciences › genetics › genomes

Programme(s)

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme

Topic(s)

• ERC-2019-POC - ERC Proof of Concept Grant

Call for proposal

ERC-2019-PoC

See other projects for this call

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

Host institution

MEDIZINISCHE HOCHSCHULE HANNOVER

Net EU contribution

€ 150 000,00

Address

Carl-neuberg-strasse 1
30625 Hannover
Germany

Region

Niedersachsen › Hannover › Region Hannover

Activity type

Higher or Secondary Education Establishments

Links

Other funding

No data

Beneficiaries (1)

MEDIZINISCHE HOCHSCHULE HANNOVER

Germany

Net EU contribution

€ 150 000,00

Address

Carl-neuberg-strasse 1
30625 Hannover

Region

Niedersachsen › Hannover › Region Hannover

Activity type

Higher or Secondary Education Establishments

Links

Other funding

No data